CD274 and hereditary clear cell renal cell carcinoma: Part A consisted of dose escalation up to 10 mcg/kg/day IV (day 1 through day 5 in 21-day cycles), Part B involved IV nemvaleukin monotherapy dose expansion in melanoma and renal cell carcinoma cohorts, and Part C evaluated the combination of nemvaleukin at 3 or 6 mcg/kg/day and pembrolizumab in 21-day cycles in patient cohorts of distinct tumor types based on previously established FDA indications for anti-PD-(L)1 agents.